Summary of Key Points
Families with rare diseases often have to migrate to areas with more favorable healthcare policies in order to keep their patients alive, a phenomenon referred to as "insurance migration." This is driven by the significant differences in local medical insurance systems (such as reimbursement caps, lists of special medications, and dual-channel access), as well as the exorbitant costs of necessary medications. Families resort to various tactics, including modifying rental contracts, transferring household registrations, affiliating with companies, or using intermediaries, to take advantage of policy loopholes. However, they constantly face updates in policies and stricter regulations, struggling between moral considerations and the imperative need to survive. Their ultimate hope is for a nationwide standard of fair healthcare.
Why Become "Migratory Birds"? The Difference in Medical Insurance Policies Can Be Lifesaving
For families with rare diseases, the difference in medical insurance policies across cities is not about the extent of benefits but whether their patients can survive:
- Reimbursement Caps: In some places, there are no limits on reimbursement; in others, the annual maximum may be only 100,000 yuan. For example, Li Xing, a hemophiliac patient in Guangxi, can only receive up to 100,000 yuan in coverage per year through his employee insurance, forcing him to limit his activities in the fourth quarter of the year. In contrast, a patient in a provincial capital in the east does not face a reimbursement cap on coagulation factor treatments, with out-of-pocket costs for medication amounting to less than 5,000 yuan per month.
- Lists of Special Medications: Some cities include expensive medications in their healthcare programs, while others do not. For instance, the drug Dacitinib, used by Songsong, a child with neuroblastoma, costs 60,000 yuan per vial and over 1 million yuan per year. However, if the city includes this drug in its program, the reimbursement can range from 30% to 70%, making it a lifeline for the patient.
- Medication Availability: In some areas, the necessary medications are not even available. Zhuzhu, a patient with primary immunodeficiency, cannot find gamma globulin in her county and must move to Changsha; Qingqing, a Hong Kong patient, had to buy a generic version of the drug, which reduced the cost from 200,000 Hong Kong dollars per month to 20,000 yuan.
What Tactics Do They Use to Survive? Modifying Contracts, Using Intermediaries, and Transferring Households
Families with rare diseases employ various strategies to access local medical insurance or healthcare programs:
- Modifying Rental Contracts: To quickly obtain a residence permit and insurance coverage, Songsong's father negotiated with the landlord to extend the rental contract by half a year, allowing them to get both the permit and insurance in just one day.
- Taking Advantage of Transfer Window Periods: Zhuzhu's mother transferred her household registration to Changsha before selling her house, ensuring she could continue to purchase medication there even after the sale.
- Affiliating with Companies or Using Intermediaries: Hemophiliac patients may affiliate with companies to obtain insurance coverage. Some intermediaries can handle the residence permit and insurance procedures for a fee of tens of thousands of yuan, even if the person has never been to the city.
- Reverse Migration to Mainland China: Qingqing's mother utilized policies for Hong Kong, Macao, and Taiwan residents to obtain mainland medical insurance, allowing her to access both generic drugs and more advanced treatment options.
The Loopholes Are Always Closing, Making Migration More Difficult
Policy loopholes do not last long before being addressed by insurance companies and regulatory authorities:
- Stricter Regulations for Healthcare Programs: A healthcare program that previously covered 60% of the cost of Dacitinib removed the drug from its list after an influx of patients and required a five-year residency requirement. Other programs set a five-year insurance period for non-residents, reducing the reimbursement limit from 1 million yuan to 300,000 yuan.
- Hospitals Refusing to Treat Patients: Zhang Xin's son required high doses of gamma globulin, which exceeded the DRG (disease-based payment) budget, and the hospital refused to treat him due to performance concerns. Zhuzhu, despite having a household registration, was also rejected by the rheumatology department and had to be treated by the gastroenterology department.
- Penalties for Affiliated Insurance: A friend of Sui Yan was caught using an affiliated company to obtain insurance coverage, resulting in the cancellation of his medical insurance and penalties for both the patient and the company. Hospital prescriptions were also reduced from monthly to weekly, increasing the travel costs for patients from other provinces.
Struggling with Loopholes While Hoping for Unified Policies
Families with rare diseases face a dilemma:
- Moral Dilemmas: They struggle with whether their actions are ethical, such as spending extra money on insurance to ensure their child's survival.
- Fear of Policy Changes: They worry that if the loopholes are closed before prices decrease, their children will be left without access to necessary treatments.
- The Ultimate Goal: Their common wish is to no longer have to migrate between cities, to buy medication and receive coverage locally. "What we really want is not to exploit policy loopholes but a fair chance to survive."
This report highlights the critical issues in rare disease healthcare: although the national medical insurance catalog has been standardized, local supplementary policies (such as healthcare programs and reimbursement limits) still force patients to migrate. The high cost of medications, uneven distribution of medical resources, and lagging policy adjustments contribute to this situation. For these families, "insurance migration" is not a choice but a matter of survival. The solution lies in reducing the disparities in regional healthcare coverage so that every patient can access life-saving treatments wherever they live.